🔗 Share this article

Given that the United States proceeds with sweeping revisions to its vaccine schedules, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on coronavirus shots throughout the pandemic and has focused upon potential fatalities after COVID-19 vaccination in her recent time at the FDA.

Planned Shifts to Pediatric Vaccine Schedule

Agency leaders had intended to announce radical revisions to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s immunization schedule, it is understood – a significant shift that would put the US at odds with many the international standard with little proof for improved outcomes. The planned update has been postponed until the new year.

In place of Vinay Prasad, Dr. Høeg is set to address the audience at the event. She was newly appointed acting director of the FDA’s CDER, the fifth person to head the office this year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a greater focus upon dismantling already-approved immunizations at the FDA.

Høeg has repeatedly called for discontinuing certain pediatric shot schedules in the US in order to be more in line with Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

Høeg has little discernible track record in drug development, approval processes or administrative roles, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have the requisite experience” for overseeing the CDER, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past commissioners of the center would “understand laws and regulations and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she lacks the kind of background that former directors who led CBER have had.”

This division has an enormous range of responsibilities at the agency, she pointed out.

“The public just zeroes in on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and so forth, and every single one have to be looked after,” she noted. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial management component to the job, which oversees more than 5,000 personnel. “It’s a massive administrative position, if you do it right,” she said.

Response and Disputed Policies

In response to concerns about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among agency officials on immunizations, a press secretary stated that the “questions stem from incorrect presumptions”.

“Her experience is consistent with the duties of her role,” the representative stated, citing the time Høeg spent counseling the agency head on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's new priority voucher program, a disputed one-day medication authorization process that reportedly concerned her former heads. “How are these drugs being picked for this fast-track system? Who is making the decisions?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards laxer rules of all drugs, with the exception of immunizations.”

Documented Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if troubling, past, some experts have noted. She released a study using unconfirmed volunteer-provided data to estimate the rate of heart inflammation after COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are riskier than they are.

Included in her “wish list” for the incoming government encompassed altering rules for novel immunizations and ending “optional” vaccines, she remarked post-election on a online show. At the agency, Høeg has according to sources floated the idea of excluding adolescent males from receiving Covid vaccinations.

“She is an all-around dogmatist who begins with her conclusions and reverse-engineers to fit the data in a extremely disingenuous, dishonest manner,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|